Physician profile
Renata A Meyer
NPI 1740635507
$1,049.32
in general payments reported to CMS, 2019-2025
21 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $73.50 · 2021: $156 · 2022: $232 · 2023: $265 · 2024: $66.11 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $297.69 | 2019-2022 | |
| Lilly USA, LLC | $156.06 | 2022-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $95.33 | 2021-2023 | |
| Glaxosmithkline, LLC. | $60.20 | 2020-2023 | Bexsero |
| Verona Pharma, INC. | $52.56 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $47.98 | 2023 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $37.99 | 2022-2024 | Flumist Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $35.73 | 2022 | |
| Sumitomo Pharma America, INC. | $35.30 | 2025 | Gemtesa |
| Abbvie INC. | $31.48 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.29 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $21.34 | 2024 | Voquezna |
| Abbott Laboratories | $21.08 | 2022 | |
| Indivior INC. | $20.09 | 2024 | Sublocade |
| Dexcom, INC. | $18.35 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $17.84 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.83 | 2022 | |
| Lundbeck LLC | $15.27 | 2023 | Rexulti |
| Exact Sciences Corporation | $13.87 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $13.03 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renata Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.